vorasidenib
servier
['vorasidenib', 'indigo']
outstanding plenary at #asco23 on vorasidenib (idh inhibitor) for idh mutant lgg in indigo double blind rct presented by ingo mellinghoff! primary endpoint met of imaging based pfs (27.7 vs 11 months) with hr of 0.39 (0.27-0.56)! paper in - 
Neuro-Oncology Postdoc @MiamiCancerInst @BaptistHealthSF

GCSRT '22 @harvardmed
MBBS '22 King George's Medical University, India

https://t.co/lZn3ye1gUY